Duos Technologies And 2 Other Stocks Under $3 Insiders Are Buying
Duos Technologies And 2 Other Stocks Under $3 Insiders Are Buying
內部人士正在買入Duos Technologies和其他兩隻低於3美元的股票
The Dow Jones index closed higher by 0.2% on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道瓊斯指數週二收盤上漲0.2％。當內部人士購買或出售股票時，這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將此視爲他們整體投資或交易決策的一個因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是細價股最近幾筆值得注意的內幕交易。欲了解更多信息，請訪問Benzinga的內幕交易平台。
Bespoke Extracts
定製提取物
- The Trade: Bespoke Extracts, Inc. (OTC:BSPK) CEO Michael Feinsod bought a total of 2,000 shares at an average price of $0.13. To acquire these shares, it cost around $268.
- What's Happening: The company's stock lost around 48% over the past six months.
- What Bespoke Extracts Does: Bespoke Extracts Inc is focused on selling its proprietary line of specially-formulated, premium quality, hemp-derived CBD products.
- 交易：Bespoke Extracts, Inc.（場外交易代碼：BSPK）首席執行官邁克爾·費恩索德共購買了2,000股股票，平均價格爲0.13美元。收購這些股票的成本約爲268美元。
- 發生了什麼：該公司的股票在過去六個月中下跌了約48％。
- Bespoke Extracts的作用：Bespoke Extracts Inc專注於銷售其專有系列的特殊配方、優質、大麻衍生的CBD產品。
Ocuphire Pharma
Ocuphire Pharma
- The Trade: Ocuphire Pharma, Inc. (NASDAQ:OCUP) CEO George Magrath acquired a total of 5,000 shares at an average price of $1.75. To acquire these shares, it cost around $8,773.
- What's Happening: On May 10, Ocuphire Pharma posted a wider-than-expected quarterly loss.
- What Ocuphire Pharma Does: Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.
- 交易：Ocuphire Pharma, Inc.（納斯達克股票代碼：OCUP）首席執行官喬治·馬格拉思共收購了5,000股股票，平均價格爲1.75美元。收購這些股票的成本約爲8,773美元。
- 發生了什麼：5月10日，Ocuphire Pharma公佈的季度虧損超出預期。
- Ocuphire Pharma做什麼：Ocuphire Pharma Inc是一家臨床階段的眼科生物製藥公司，專注於開發和商業化治療屈光和視網膜眼病的療法。
Duos Technologies
Duos 科技
- The Trade: Duos Technologies Group, Inc. (NASDAQ:DUOT) CEO Charles Parker Ferry acquired a total of 3,773 shares at an average price of $2.70. The insider spent around $10,187 to buy those shares.
- What's Happening: On May 13, Duos Technologies Group reported weaker than expected first-quarter sales.
- What Duos Technologies Does: Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs.
- 交易：Duos Technologies Group, Inc.（納斯達克股票代碼：DUOT）首席執行官查爾斯·帕克·費裏共收購了3,773股股票，平均價格爲2.70美元。知情人士花費了約10,187美元購買了這些股票。
- 發生了什麼：5月13日，Duos Technologies集團報告稱，第一季度銷售額低於預期。
- Duos Technologies的業務：以其品牌名稱duostech運營的Duostech集團公司設計、開發、部署和運營智能技術解決方案，爲鐵路、物流和多式聯運業務提供支持，從而簡化運營、提高安全性並降低成本。
Read More: Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
閱讀更多：本月可能挽救您的投資組合的五大醫療保健股票
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。